07:31 AM EDT, 10/15/2024 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) , a clinical-stage biotechnology company, on Tuesday said that peer-reviewed journal Lancet Rheumatology, recently published Eupraxia's Phase 2 data from its Springboard trial evaluating EP-104IAR for the treatment of knee osteoarthritis.

The study confirmed that EP-104IAR gave "clinically significant and durable" pain relief in trial participants.

"The publication of our Phase 2b data in a distinguished and respected journal such as Lancet Rheumatology raises the profile of EP-104IAR and further underscores the potential of this product candidate to become a best-in-class therapy for the treatment of knee osteoarthritis," said Dr. James Helliwell, CEO of Eupraxia.